Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pediatr Hematol Oncol. 2011 Oct;33(7):524-8. doi: 10.1097/MPH.0b013e318223d0c1.

Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray.

Author information

  • 1Tumor and Metastasis Biology Section, Pediatric Oncology Branch, National Institutes of Health, Bethesda, MD 20892, USA. osbornet@mail.nih.gov

Abstract

The ability to define osteosarcoma (OS) patients at greatest risk for metastatic progression and nonresponsiveness to conventional therapy is currently not possible. Such biomarkers are needed to predict overall prognosis, probability of metastases at diagnosis, and response to chemotherapy. The tissue microarray (TMA) serves as a powerful tool for detecting and validating protein biomarkers across a variety of patients. We constructed a novel outcome-linked TMA to add to and address shortcomings of currently available OS tissue resources. To test the use of our TMA, we surveyed the expression of eukaryotic initiation factor 4E (eIF4E) in OS patients using immunohistochemistry. Aberrant regulation of translation initiation is a feature of many cancers. eIF4E is central to initiation of protein synthesis. Its expression and activity have been implicated in tumor formation and potentially malignant and/or metastatic progression in some carcinomas. We found that eIF4E was uniformly expressed in OS patient samples. No association was found between eIF4E and outcome in OS patients. This novel OS TMA provided a facile mechanism to assess the role of a relevant protein biomarker in OS.

PMID:
21941146
PMCID:
PMC3179611
DOI:
10.1097/MPH.0b013e318223d0c1
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Support Center